Teva Can Launch Neupogen Biosimilar One Month Before Patent Expiration
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a settlement with Amgen, Teva can begin selling its G-CSF product in November 2013; the launch may be sooner if a third party launches or wins an infringement suit.